Dopamine Agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study
Open Access
- 10 June 2009
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in BMC Neurology
- Vol. 9 (1), 23
- https://doi.org/10.1186/1471-2377-9-23
Abstract
Background Psychosis is rare in untreated patients with Parkinson's disease (PD) but the prevalence rises to 40% during dopaminergic treatment. So far, no systematic comparison of the psychogenic potential of different dopaminergic drugs had been performed. Methods Eighty PD patients with psychotic episodes were compared to an age-matched control group of PD patients without psychotic episodes (n = 120) in a cross-sectional retrospective study. Results We found a positive correlation between psychotic episodes and dementia, number of concomitant medication, and pergolide intake. Odds ratio calculation confirmed the association with dementia. With respect to dopaminergic treatment, pergolide showed the highest odds ratio, levodopa the lowest. An adjusted logistic regression model confirmed the strong association with psychotic episodes and pergolide and no association with levodopa (adjusted odds ratio 2.01 and 0.11, respectively). Conclusion The analysis indicates that dementia and concomitant medication are factors in PD associated with psychotic symptoms. Furthermore, different dopaminergic drugs showed markedly different associations with psychotic symptomsKeywords
This publication has 48 references indexed in Scilit:
- Rotigotine transdermal patch in early Parkinson's disease: A randomized, double‐blind, controlled study versus placebo and ropiniroleMovement Disorders, 2007
- Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stressJournal of Neurology, Neurosurgery & Psychiatry, 2007
- Frequency and correlates of co-morbid psychosis and depression in Parkinson's diseaseParkinsonism & Related Disorders, 2006
- Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET studyMovement Disorders, 2006
- High doses of pergolide improve clinical global impression in advanced Parkinson's disease—A preliminary open label studyArchives of Gerontology and Geriatrics, 2005
- The Parkinson–Control study: A 1‐year randomized, double‐blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's diseaseMovement Disorders, 2005
- Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. III. Agonist and Antagonist Properties at Serotonin, 5-HT1 and 5-HT2, Receptor SubtypesJournal of Pharmacology and Experimental Therapeutics, 2002
- Visual hallucinations in psychologically normal people: Charles Bonnet's syndromeThe Lancet, 1996
- Pergolide compared with bromocriptine in Parkinson's disease: A multicenter, crossover, controlled studyMovement Disorders, 1994
- Psychiatric aspects of Parkinson's disease.BMJ, 1989